ArticleProceedings of the National Academy of Sciences of the United States of America2003
Molecular classification of familial non-BRCA1/BRCA2 breast cancer.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed.
- Targeted sequencing reveals the somatic mutation landscape in a Swedish breast cancer cohort.Scientific reports · 2020Article
- GermlineFrontiers in genetics · 2020Article
- Reparameterization of PAM50 Expression Identifies Novel Breast Tumor Dimensions and Leads to Discovery of a Genome-Wide Significant Breast Cancer Locus atCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2018Article
- Generation and characterization of monoclonal antibodies that recognize human and murine supervillin protein isoforms.PloS one · 2018Article
- Transcriptional signature of lymphoblastoid cell lines ofOncotarget · 2017Article
- Proteomic analysis of breast tumors confirms the mRNA intrinsic molecular subtypes using different classifiers: a large-scale analysis of fresh frozen tissue samples.Breast cancer research : BCR · 2016Article
- Pyrosequencing quantified methylation level of BRCA1 promoter as prognostic factor for survival in breast cancer patient.Oncotarget · 2016Article
- Promoter methylation and expression changes ofOncology letters · 2015Article
- RNA profiling reveals familial aggregation of molecular subtypes in non-BRCA1/2 breast cancer families.BMC medical genomics · 2014Article
- Hereditary breast cancer: clinical, pathological and molecular characteristics.Breast cancer : basic and clinical research · 2014Review
- MicroRNA-based molecular classification of non-BRCA1/2 hereditary breast tumours.British journal of cancer · 2013Article
- The complex genetic landscape of familial breast cancer.Human genetics · 2013Review
- DNA copy number profiling reveals extensive genomic loss in hereditary BRCA1 and BRCA2 ovarian carcinomas.British journal of cancer · 2013Article
- Article
- Methylation of BRCA1 promoter region is associated with unfavorable prognosis in women with early-stage breast cancer.PloS one · 2013Article
- Article
- HIF-1α overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers.PloS one · 2013Article
- Genetic anticipation is associated with telomere shortening in hereditary breast cancer.PLoS genetics · 2011Article
- Methylated genes in breast cancer: associations with clinical and histopathological features in a familial breast cancer cohort.Cancer biology & therapy · 2011Article
- Pathology of hereditary breast cancer.Cellular oncology (Dordrecht, Netherlands) · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
In the decade since their discovery, the two major breast cancer susceptibility genes BRCA1 and BRCA2, have been shown conclusively to be involved in a significant fraction of families segregating breast and ovarian cancer. However, it has become equally clear that a large proportion of families segregating breast cancer alone are not caused by mutations in BRCA1 or BRCA2. Unfortunately, despite intensive effort, the identification of additional breast cancer predisposition genes has so far been unsuccessful, presumably because of genetic heterogeneity, low penetrance, or recessive/polygenic mechanisms. These non-BRCA1/2 breast cancer families (termed BRCAx families) comprise a histopathologically heterogeneous group, further supporting their origin from multiple genetic events. Accordingly, the identification of a method to successfully subdivide BRCAx families into recognizable groups could be of considerable value to further genetic analysis. We have previously shown that global gene expression analysis can identify unique and distinct expression profiles in breast tumors from BRCA1 and BRCA2 mutation carriers. Here we show that gene expression profiling can discover novel classes among BRCAx tumors, and differentiate them from BRCA1 and BRCA2 tumors. Moreover, microarray-based comparative genomic hybridization (CGH) to cDNA arrays revealed specific somatic genetic alterations within the BRCAx subgroups. These findings illustrate that, when gene expression-based classifications are used, BRCAx families can be grouped into homogeneous subsets, thereby potentially increasing the power of conventional genetic analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.